On Friday, MFA Financial, Inc. (NYSE:MFA)’s shares declined -1.66% to $7.69.
MFA Financial, Inc. (MFA) declared that in accordance with the terms of its 7.50% Series B Cumulative Redeemable Preferred Stock, the Board of Directors has declared a preferred stock dividend of $0.46875 per share for the quarter ending June 30, 2015. This dividend is payable on June 30, 2015, to preferred stockholders of record as of June 2, 2015.
MFA Financial, Inc., a real estate investment trust (REIT), invests in residential agency and non-agency mortgage-backed securities (MBS), and residential whole loans in the United States (the U.S.). Its MBS are secured by hybrid mortgages, adjustable-rate mortgages, and 15-year and longer term fixed-rate mortgages, in addition to by mortgages that have interest rates that reset more frequently.
China Information Technology, Inc. (NASDAQ .CNIT)’s shares gained 15.81% to $3.59.
China Information Technology, Inc. (CNIT) declared that the Company attended the 2015 Guiyang International Big Data Expo (“Expo”) that took place in Guiyang City from May 26, 2015 through May 29, 2015. At the Expo, the Company reached planned partnership with the Guiyang municipal government to collaborate on the “CNIT Internet + Smart Guiyang” project. Other participants of the project comprise Huawei Technologies Co., Ltd. (“Huawei”), China Potevio Co., Ltd. (“China Potevio”), and Guizhou Zhiyuan IT Incubator Co., Ltd.
The 2015 Guizhou Big Data Expo was an industry summit that exhibited the latest developments in big data technologies and offered a world-class platform for exchanging business ideas. Themed Big Data Security and Development in the Era of ‘Internet Plus,’ this year’s summit attracted industry leaders from around the world such as Alibaba, Baidu, Intel, Lenovo and Microsoft. At the opening ceremony, a congratulatory letter from Premier Li Keqiang commented that China’s “Internet Plus Strategy” is poised to promote innovative business models across different industries, which will assist achieve medium to high-speed economic growth.
China Information Technology, Inc. operates as an Internet service company that provides cloud-based platform, exchange, and big data solutions enabling innovation and smart living in the education, healthcare, new media, finance, and transportation sectors in the People’s Republic of China. The company, through its proprietary Cloud-App-Terminal model, provides Cloud Nest big data services to the traditional media industry.
At the end of Friday’s trade, Outfront Media Inc (NYSE:OUT)‘s shares dipped -1.52% to $27.84.
Outfront Media Inc (OUT) launched OUTFRONT Studios as its in-house full-service creative boutique to design advertising campaigns for clients. By utilizing an innovative network spanning the United States, OUTFRONT Studios will deliver groundbreaking campaigns that are impactful and engaging. The first-of-its-kind within the out-of-home space, Studios will focus on producing original creative for use on its out-of-home network.
OUTFRONT Media Inc. provides advertising space on out-of-home advertising structures and sites in the United States, Canada, and Latin America. Its portfolio primarily comprises of billboard displays, which are principally located on the heavily traveled highways and roadways; and transit advertising displays with multi-year contracts with municipalities in various cities across the United States.
Kite Pharma Inc (NASDAQ:KITE), ended its Friday’s trading session with 14.21% gain, and closed at $62.19.
Moffitt Cancer Center has treated the first patient nationally in Kite Pharma’s (KITE) Phase 1/2 clinical trial of KTE-C19. The trial comprises an investigational therapy for patients with refractory aggressive non-Hodgkin’s lymphoma (NHL).
KTE-C19 is an investigational therapy in which a patient’s T cells are genetically modified to express a chimeric antigen receptor (CAR) designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias.
Trial sponsor, Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous T-cell therapy (eACTTM) designed to restore the immune system’s ability to recognize and eradicate tumors.
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
